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Abstract
Background: The human gut microbiome performs important functions in human health and disease. A classic
example for host-gut microbial co-metabolism is host biosynthesis of primary bile acids and their subsequent
deconjugation and transformation by the gut microbiome. To understand these system-level host-microbe
interactions, a mechanistic, multi-scale computational systems biology approach that integrates the different types
of omic data is needed. Here, we use a systematic workflow to computationally model bile acid metabolism in gut
microbes and microbial communities.
Results: Therefore, we first performed a comparative genomic analysis of bile acid deconjugation and biotransformation
pathways in 693 human gut microbial genomes and expanded 232 curated genome-scale microbial metabolic
reconstructions with the corresponding reactions (available at https://vmh.life). We then predicted the bile acid
biotransformation potential of each microbe and in combination with other microbes. We found that each microbe
could produce maximally six of the 13 secondary bile acids in silico, while microbial pairs could produce up to 12 bile
acids, suggesting bile acid biotransformation being a microbial community task. To investigate the metabolic potential of
a given microbiome, publicly available metagenomics data from healthy Western individuals, as well as inflammatory
bowel disease patients and healthy controls, were mapped onto the genomes of the reconstructed strains. We
constructed for each individual a large-scale personalized microbial community model that takes into account strain-level
abundances. Using flux balance analysis, we found considerable variation in the potential to deconjugate and transform
primary bile acids between the gut microbiomes of healthy individuals. Moreover, the microbiomes of pediatric
inflammatory bowel disease patients were significantly depleted in their bile acid production potential compared with
that of controls. The contributions of each strain to overall bile acid production potential across individuals were found to
be distinct between inflammatory bowel disease patients and controls. Finally, bottlenecks limiting secondary bile acid
production potential were identified in each microbiome model.
Conclusions: This large-scale modeling approach provides a novel way of analyzing metagenomics data to accelerate
our understanding of the metabolic interactions between the host and gut microbiomes in health and diseases states.
Our models and tools are freely available to the scientific community.
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Introduction
The human gut microbiome performs essential functions
for human health and is directly implicated in the patho-
genesis of complex diseases, such as inflammatory bowel
disease, obesity, and type II diabetes [1]. Since the eti-
ology of these diseases is multifactorial, they can be seen
as having a malfunctioning network rather than a single
cause [1]. To understand the interplay between the fac-
tors underlying the disease network, such as genome,
microbiome, and diet, computational systems biology
approaches are necessary to integrate the different
-omes, such as metagenome and metabolome, and to
identify key interactions in an unbiased manner [1].
Such data-driven systems biology approaches could also
identify drug-network interactions [1] and predict indi-
vidual treatment responses in patients [1, 2].
One important function carried out by the human gut
microbiome is the deconjugation of human primary bile
acids and their subsequent biotransformation to second-
ary bile acids with implications for human health [3].
Briefly, the human liver synthesizes the primary bile
acids cholate (CA) and chenodeoxycholate (CDCA),
which are each conjugated with either taurine or glycine
[4]. Conjugated bile acids are stored in the gall bladder
and released into the small intestine after a meal [4]. In
the intestine, they are subject to extensive metabolism
by gut microbes, namely deconjugation of glycine or tau-
rine, and biotransformation of the unconjugated primary
bile acids to secondary bile acids [4]. Primary and
secondary bile acids have endocrine functions and
modulate host metabolism [3]; thus, their composition
has important implications for human health. A link
between microbial bile acid metabolism and inflamma-
tory bowel disease (IBD), i.e., ulcerative colitis and
Crohn’s Disease, has been repeatedly demonstrated [5].
In IBD patients, fecal conjugated bile acid levels are
higher while secondary bile acid levels are lower and the
deconjugation and transformation abilities of IBD-asso-
ciated microbiomes are impaired [5]. Other diseases that
have been associated with alterations of the intestinal
bile acids pool include liver cirrhosis, liver cancer, irrit-
able bowel syndrome, short bowel syndrome, and obesity
[3, 6]; however, a mechanistic understanding of these
bile acid-microbiome-disease associations is lacking.
Thus, the role of bile acid composition and its relation-
ship with the gut microbiome in these diseases needs to
be elucidated and to be considered for therapeutic op-
tions [6].
A well-established computational approach for model-
ing human and microbial metabolism is Constraint-
based Reconstruction and Analysis (COBRA) [7]. The
COBRA approach relies on having genome-scale recon-
struction of a target organism, which assembled based
on the organism’s genome sequence and manually
curated against the available genomic data and literature
following established protocols [8]. A genome-scale re-
construction can readily be converted into a mathemat-
ical model, in which reactions and metabolites are
represented as a stochiometric matrix, and interrogated
using established methods such as flux balance analysis
(FBA) [9]. Briefly, FBA relies on physicochemical (e.g.,
mass-charge balance) and environmental (e.g., nutrient
uptake) constraints that limit the flow of metabolites
through the network resulting in a solution space of
feasible flux distributions [9]. Generally, FBA relies on
the definition of an objective function, such as the bio-
mass reaction, which sums all known precursors
required to form a new cell. The objective function is
then minimized or maximized, and the optimal solution,
aka flux distribution, under the given condition-specific
constraints is computed [9]. FBA operates under the
steady-state assumption and as such does not require
kinetic parameters to compute an optimal solution [9].
Through implementation of condition-specific con-
straints, e.g., a certain dietary regime, COBRA simula-
tions have provided further insight into the metabolic
capabilities of, e.g., human intestinal microbes [10–14],
for which a comprehensive collection of reconstructions
(AGORA) has been published [15, 16]. An advantage of
the COBRA approach for microbial community model-
ing is that the underlying genome-scale metabolic net-
works enable mechanistic predictions of metabolic
fluxes in each individual species while taking into
account biological features, such as substrate availability
or species-species boundaries [17, 18]. Previous studies
have already demonstrated the use of constraint-based
multi-species models for the prediction of host-microbe
interactions [12, 19] and gut microbial community inter-
actions [13, 20]. COBRA models can also be contextual-
ized through omics data, e.g., metagenomic data [2, 14].
More importantly, by mapping metagenomic data of an
individual, the metabolic microbial community model is
personalized to this individual enabling the prediction of
personalized metabolic profiles, which can be used to
ultimately stratify disease and control groups [2, 14].
Results
To investigate the microbiome-level bile-acid production
potential of healthy individuals and IBD patients, we de-
rived a systematic, reproducible workflow (Fig. 1). First,
we expanded bile acid metabolism pathways captured in
232 gut microbial reconstructions using state-of-the-art
comparative genomics methods. We then joined these
reconstructions into pairwise microbial models and pre-
dicted their potential to cooperatively produce secondary
bile acids. While each microbe could only produce up to
six of the 13 secondary bile acids in silico, microbial
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pairs could produce up to 12 of the 13 bile acids,
highlighting bile acid biotransformation as a microbial
community task. Subsequently, we constructed func-
tional and personalized gut microbiome models using
metagenomics data from healthy and IBD individuals to
predict an individual’s bile acid biosynthesis potential.
We found inter-individual variation in the production
capability of bile acids in healthy individuals as well as
significant differences between healthy and IBD micro-
biomes. Moreover, we were able to compute the contri-
bution of each strain to bile acid deconjugation and
transformation while taking the metabolic network of
the whole microbiome community and the applied con-
straints (e.g., dietary uptake) into account. Finally, we
identified bottlenecks limiting the biotransformation
potential into secondary bile acids. This mechanistic,
microbiome-wide modeling approach can be readily
applied to the personalized computation of other health-
relevant human-microbial co-metabolites.
Distribution of microbial bile acid deconjugation and
biotransformation pathways across taxa
To determine how widely genes encoding for bile acid
pathways are spread in human gut microbes, we per-
formed a systematic comparative genomic analysis of the
bile acid deconjugation and transformation pathway
(Fig. 2), starting with previously characterized enzymes
for primary bile acid deconjugation [21] and transform-
ation into secondary bile acids [22–25]. Of the currently
818 microbial AGORA reconstructions, which include
46 newly reconstructed gut microbes (see the “Materials
and methods” for details), only 670 genomes were avail-
able at the PubSEED database [26, 27]. We additionally
analyzed 23 further microbial genomes, yielding a total
of 693 considered genomes (Fig. 1a). We found the bile
salt hydrolase (bsh) gene, which encodes the deconjuga-
tion of conjugated primary bile acids, in 204 of the 693
(29%) genomes, including two archaeal genomes, Metha-
nobrevibacter smithii ATCC 35061 and Methanosphaera
Fig. 1 Schematic overview of the workflow in this study. a Comparative genomic and metabolic reconstruction approach used to expand the
AGORA [15] resource with a bile acid (BA) deconjugation and biotransformation subsystem. The comparative genomic approach was performed
in the PubSEED [26, 27] platform. Quality controland quality assurance (QC/QA) during reaction and metabolite formulation and addition to the
AGORA reconstructions were ensured by using the reconstruction tool rBioNet [74]. b Computational pipeline used to predict the sample-specific
bile acid deconjugation and biotransformation by human gut microbiomes. First, publicly available metagenomic data was retrieved from HMP
[35], and the COMBO/PLEASE [36, 37] cohort. Next, the strain-level abundances were mapped onto the reference set of AGORA genomes.
Microbial community models were constructed using the illustrated workflow, as implemented in the Microbiome Modeling Toolbox [33], and
they account for the strain-level composition of each individual microbiome. Finally, each personalized community model was constrained with
an “Average European” diet supplemented with conjugated primary bile acids and its individual-specific, primary bile acid deconjugation and
biotransformation potential was computed using flux balance analysis [9, 76].
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stadtmanae DSM 3091 (Additional file 1: Table S1). The
distribution of the bsh gene in Actinobacteria, Bacteroi-
detes, Firmicutes, as well as the two archaea (Fig. 2,
Additional file 2: Figure S1) was in line with previously
reported results [21]. Additionally, the bsh gene was
found in 22 Proteobacteria genomes (Additional file 1:
Table S1). Among all analyzed hydroxysteroid dehydro-
genases (HSDHs), 7α-HSDH was the most widespread
enzyme as it was found in 46 of the 693 (7%) genomes
(Additional file 1: Table S1 and Additional file 2: Figure
S2). Additionally, 3α-, 3β-, and 7β-HSDHs were found in
17, 12, and 3 genomes, respectively (Additional file 1:
Table S1 and Additional file 2: Figure S2). Using results
from a recent work [24], we found the 12α-HSDH in 39
genomes, which belonged mostly to Firmicutes represen-
tatives (Additional file 1: Table S1). We could not find the
12α-HSDH in the Clostridium leptum genome, although
the enzymatic activity has been demonstrated [28].
The bile acid-inducible (bai) gene cluster for the mul-
tistep 7α/β-dehydroxylation pathway, which has been
reported for Clostridiaceae and Eggerthella spp. [4, 23],
was found in seven analyzed genomes belonging to
Clostridioides sp., Lachnoclostridium sp., and Eggerthella
sp. (Additional file 2: Figure S2). Remarkably, all these
genomes also have genes for 12α-HSDH as well as either
7α-HSDH or genes for both 3α- and 3β-HSDHs
(Additional file 1: Table S1). Thus, these microbes could
play a crucial role in biotransformation of bile acids in
the human intestine. The genes encoding for the last
two steps of the 7α/β-dehydroxylation pathway, i.e., the
NADH-dependent reduction and the export of second-
ary bile acids (Fig. 2c–e), have not been identified.
Recently, the baiN gene was shown to encode a
bi-functional enzyme NADH-dependent Δ6/Δ4-hy-
droxysteroid reductase (Fig. 2) [29]. We analyzed the
genomic context of this gene and found it in the C. scin-
dens genome to be chromosomally co-localized with the
gene for a probable NAD(FAD)-utilizing dehydrogenase
(CLOSCI_00522). This chromosomal clustering was con-
served in all Clostridiales genomes having the bai path-
way, except for Clostridium hiranonis DSM 13275
(Additional file 2: Figure S3). It has been previously
Fig. 2 Illustration of bile acid pathways in human gut microbes reconstructed for AGORA. a Deconjugation of Tauro-CA/Glyco-CA and
subsequent conversion to 12-dehydro-CA, UCA, and Iso-CA. b Deconjugation of Tauro-CDCA/Glyco-CDCA and subsequent conversion to UDCA. c
Conversion of CA to DCA via the bai pathway. d Conversion of CDCA to LCA via the bai pathway. e Conversion of UDCA to LCA via the bai
pathway. CoA Coenzyme A. For metabolite abbreviations, see Table 1.
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shown that genes encoding enzymes for the same meta-
bolic pathway are often clustered on chromosome and
such a clustering is conserved in genomes of related or-
ganisms [30]. Thus, the genes baiN and CLOSCI_00522
can possibly belong to the same metabolic pathway,
\namely bai pathway. The enzyme for the last step of the
bai pathway, NADH-dependent 3α-hydroxysteroid reduc-
tase, is unknown. Because the product of CLOSCI_00522 is
a NADH-depended reductase, we propose that product is
an enzyme catalyzing the final reaction of the bai pathway
(Fig. 2) and rename the gene to baiO. The bai pathway has
also been found in Eggerthella lenta [23]; consequently, we
searched for orthologs of the baiNO genes in the E. lenta
genome. Because C. scindens and E. lenta belong to differ-
ent phyla, we defined orthologs of the analyzed genes as
best/symmetrical bidirectional hits (see the “Materials and
methods” section). An ortholog of the BaiN in E. lenta is
likely to be encoded by the gene Elen_1017 (protein iden-
tity = 32%, e-value for the protein alignment = 3e−44),
whereas the BaiO ortholog was encoded by the gene
Elen_1018 (identity = 45%, e-value = e−126). These genes
were co-localized in E. lenta’s genome as well in genomes
of Eggerthella sp. 1_3_56FAA and Eggerthella sp. HGA1
(Additional file 2: Figure S3). Additionally, these genes
were co-localized with a gene encoding for a probable
transporter (Elen_1016) in the genomes of E. lenta and
Eggerthella sp. HGA1. Hence, the gene Elen_1016 was
assumed to encode a transporter for the products of the
bai pathway and was named here baiP. An ortholog of this
gene (CLOSCI_01264, identity = 59%, e-value = e−180) was
found in C. scindens genome as well in other genomes of
Clostridiaceae, having the bai pathway (Additional file 2:
Figure S3), whereas in the C. hiranonis genome, this gene
was co-localized with the baiO gene. Phylogenetic analysis
of the BaiNOP proteins and their homologs revealed that
BaiN and BaiO proteins of Eggerthella spp. and Clostri-
diales are phylogenetically distant from each other
(Additional file 2: Figure S4 and S5), whereas BaiP proteins
from these groups of genomes are phylogenetically close
(Additional file 2: Figure S6).
In summary, our comparative genomics results
expanded substantially our knowledge about bile acid
deconjugation and transformation in gut microbes, while
being consistent with previous studies [21–25]. Conse-
quently, we propose that 253 of the 693 analyzed intes-
tinal microbes (37%) can deconjugate and/or transform
bile acids, including 232 reconstructed AGORA organ-
isms (Additional file 1: Table S1, Fig. 1a).
Expansion of the gut microbial genome-scale
reconstructions by a species-specific bile acid subsystem.
The manual curation and refinement of genome-scale re-
constructions is an iterative process [8]. Species-specific
pathways are typically absent in draft reconstructions [31].
Since we did not explicitly account for bile acid pathways
in the curation of AGORA [15] prior to the present paper,
this subsystem was absent. The 232 metabolic reconstruc-
tions found to carry bile acid enzymes (Additional file 1:
Table S1) were expanded with the corresponding metabo-
lites and reactions, while ensuring functionality of the in-
cluded pathways, following established procedures [8, 32]
(see “Materials and methods” section). The complete re-
constructed bile acid biotransformation subsystem
contained 39 bile acid metabolites and 82 reactions (Fig. 2,
Table 1, Additional file 1: Table S2a, b). For CA, CDCA,
and the 13 secondary bile acids (Table 1), transport and
exchange reactions enabling the uptake and secretion of
these metabolites were added to the corresponding recon-
structions. Taken together, we expanded the AGORA
reconstructions with a bile acid module thus further im-
proving their predictive potential and enabling their use
for large-scale simulations of bile acid deconjugation and
transformation.
Investigating the complementary capabilities of human
gut microbes in silico
The majority of primary bile acids, released by the
human gallbladder into the intestine, where the gut
microbiome encounters them, are conjugated to glycine
or taurine [3]. However, many strains capable of synthe-
sizing secondary bile acids do not possess the bile salt
hydrolase (Additional file 1: Table S1) and thus, rely on
bile salt hydrolase-encoding strains to access the decon-
jugated primary bile acids.
To determine the capability of each strain alone to con-
vert the deconjugated primary bile acids into secondary
bile acids, the 232 corresponding AGORA reconstructions
were converted into condition-specific models by applying
an Average European diet supplemented with taurocholate
(Tauro-CA), glycocholate (Glyco-CA), taurochenodeoxy-
cholate (Tauro-CDCA), and glycochenodeoxycholate
(Glyco-CDCA) (Additional file 1: Table S3) as modeling
constraints. The maximally possible production flux for
the 13 secondary bile acids was predicted for each strain
using flux balance analysis [9] while setting the corre-
sponding exchange reactions as the objective function (see
the “Materials and methods” section). A total of nine
strains could synthesize 7-ketodeoxycholate (7-keto-DCA)
and 7-dehydrochenodeoxycholate (7-dehydro-CDCA)
from the conjugated primary bile acids as they possessed
both the bile salt hydrolase and the 7α-HSDH (Table 1). In
contrast, no single strain was capable of synthesizing
12-dehydrocholate (12-dehydro-CA), ursocholate (UCA),
and UDCA from the conjugated primary bile acids. Of the
five strains carrying the bai gene cluster, only Clostrid-
ium hiranonis TO-931 could synthesize LCA and DCA
from the conjugated primary bile acids (Table 1) as it
also possessed the bile salt hydrolase enzyme in
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contrast to the other four strains. Taken together, only
few strains could both deconjugate and biotransform
primary acids in isolation.
To investigate whether pairwise combinations of cer-
tain strains could complement each other’s bile acid
pathways, the 232 bile acid-producing AGORA models
were joined in every possible combination resulting in
26,796 pairwise models using the Microbiome Modeling
Toolbox [33], a COBRA Toolbox [34] extension. When
comparing the bile acid production capabilities of the
pairwise models with the respective single-strain models
on the bile acid-supplemented “Average European” diet,
we identified 7673 microbe pairs (29%) that could
synthesize at least one secondary bile acid whereas the
respective two individual strains were incapable to do so,
resulting in 19,883 cooperative bile acid syntheses (Fig.
3a, Additional file 1: Table S5). For example, 3135/7673
pairs (40.9%) could synthesize 12-dehydro-CA from
Glyco-CA or Tauro-CA (Additional file 1: Table S5).
Further, 736 pairs (2.7%) and 100 pairs (0.4%) could
synthesize DCA/LCA and UCA/UDCA, respectively,
from the conjugated primary bile acids (Additional file 1:
Table S5), demonstrating distinct bile acid synthesis cap-
abilities of microbial pairs. There was no pairwise com-
bination enabling synthesis of all secondary bile acids as
the maximal number of secondary bile acids to be syn-
thesized by any pair was 12 out of 13 (Fig. 3a). Taken
together, while only few strains were capable of both bile
acid deconjugation and biotransformation, many of the
microbial pairs are predicted to synthesize secondary
bile acids from the conjugated bile acids. This example
demonstrates that constraint-based modeling is an effi-
cient approach to elucidate the combined capabilities
present in thousands of microbe pairs compared with
the single microbes. The presented computational work-
flow could readily be applied to other microbial path-
ways of interest, in which enzymes are distributed across
multiple taxa in an ecosystem.
Large-scale modeling of the interpersonal variation in the
bile acid deconjugation and transformation of gut
microbiomes.
We next aimed to predict the bile acid deconjugation
and biotransformation potential of individual-specific
gut microbiomes. It is well known that bile acid metab-
olism is altered in individuals with IBD [3]. We were in-
terested whether personalized modeling could provide
novel insight into the differences in bile acid deconjuga-
tion and biotransformation potential between the micro-
biomes of IBD patients and controls as well as elucidate
species contributing to the pathways. For comparison,
we also evaluated the range in bile acid metabolic cap-
abilities in healthy adults. We used metagenomic data
from two sources: (1) 149 healthy American donors aged
Table 1 Overview of primary and secondary bile acids. VMH Virtual Metabolic Human database (https://vmh.life) [16]. AGORA, a
compendium of 818 curated genome-scale gut microbial metabolic reconstructions used in this study.
Name Abbreviation VMH ID Type Producer




Cholate CA cholate Primary/unconjugated Human; released by 185/818 AGORA strains
Chenodeoxycholate CDCA C02528
12-dehydrocholate 12-dehydro-CA 12dhchol Secondary 38/818 AGORA strains
7-ketodeoxycholate 7-keto-CA 7ocholate 41/818 AGORA strains
7-dehydrochenodeoxy-cholate 7-dehydro-CDCA 7dhcdchol
3-dehydrocholate 3-dehydro-CA 3dhchol 16/818 AGORA strains
3-dehydrochenodeoxy-cholate 3-dehydro-CDCA 3dhcdchol
Isocholate Iso-CA isochol 11/818 AGORA strains
Isochenodeoxycholate Iso-CDCA icdchol




Ursocholate UCA uchol 3/818 AGORA strains
Ursodeoxycholate UDCA HC02194
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18–40 years provided by the Human Microbiome Project
Consortium [35] and (2) 20 children with newly diag-
nosed Crohn’s disease and microbial dysbiosis and 25
healthy controls (COMBO/PLEASE cohort [36, 37]).
Using strain-level abundances, after mapping the reads
onto the reference set of AGORA genomes [38], we gen-
erated personalized microbiome community models for
each of the 194 sample by joining the corresponding
Fig. 3 The predicted bile acid metabolic profiles of microbe-microbe pairs and individual gut microbiomes. a Complementary bile acid
biosynthesis capabilities of the 232 gut microbial models with bile acid pathways joined in all possible combinations. The numbers of secondary
bile acids (out of 13), which can be produced by each pair, are shown. b, c Total secretion potential in the healthy adults (Healthy_HMP), IBD
patients (IBD_pediatric), and healthy pediatric controls (Healthy_pediatric) (flux values are given in mmol × person-1 × day-1): b deconjugated
cholate, c 12-dehydro-CA. Significant difference (p value < 0.001) is indicated by stars. d Principal Coordinates Analysis of the strain-level
contributions to two deconjugated primary and 13 secondary bile acids for the healthy adults, IBD patients, and healthy pediatric controls. Details
on the strain to metabolite contributions are shown in Additional file 1: Table S8, and in Additional file 2: Figure S7.
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metabolic reconstructions (Fig. 1b, the “Materials and
methods” section ). Each microbiome model was con-
strained with the “Average European” diet supplemented
with conjugated primary bile acids (Additional file 1:
Table S3). A typical personalized microbiome model
contained 127 AGORA models and 142,000 reactions
(Table 2) making this work one of the largest
constraint-based modeling efforts to date.
The bile acid deconjugation and biotransformation
potential is variable in healthy individuals and depleted
in Crohn’s Disease patients
To predict the maximally possible bile acid deconjuga-
tion and biotransformation potential of the 194 micro-
biome models, we performed flux balance analysis while
maximizing for the fecal secretion reaction flux (mmol ×
person-1 × day-1) of the primary bile acids, CA and
CDCA, and 13 secondary bile acids (Fig. 3b, c and Add-
itional file 1: Table S6). The quantitative production po-
tential varied significantly between the models, with the
quantitative production potential of LCA and DCA vary-
ing by a factor of 100 (Additional file 1: Table S6). A
statistical analysis (Wilcoxon rank sum test, with p
values adjusted for false discovery rate (FDR) by
Benjamini-Hochberg method) was performed on the
total community production potential of the 20 IBD pa-
tients (IBD_pediatric) and the 25 control microbiomes
(Healthy_pediatric) (Fig. 3b, c, Additional file 1: Table
S7). Compared with the microbiomes of healthy chil-
dren, the IBD patient microbiomes were significantly de-
pleted in 12-dehydrocholate production potential (p
value < 0.001). Primary bile acid deconjugation potential
was lower in IBD patients but only borderline significant
after adjustment for FDR (adjusted p value = 0.0551);
however, the abundance of the bile salt hydrolase reac-
tion was significantly reduced in IBD microbiomes (p
value 0.0235, Additional file 1: Table S7) and also dif-
fered based on phylum-and genus-level reaction abun-
dances for many taxa (Additional file 1: Table S7).
Microbiomes with low CA/CDCA liberation potential
from the conjugated bile acids also had a low secondary
bile acid potential (Additional file 1: Table S6) in agree-
ment with the fact that the bile salt hydrolase is the
gateway reaction in the pathway [39]. Taken together, we
predicted the inter-person variability in the bile acid bio-
synthesis potential with microbiomes from IBD patients
being significantly depleted in bile acid deconjugation
and biotransformation potential, consistent with reports
that IBD patients have higher levels of fecal conjugated
and lower levels of secondary bile acids [5].
Functional analysis of strain-level contributions in each
microbiome.
What is the contribution of individual strains to the
overall bile acid deconjugation and biotransformation
potential? While previous studies have correlated certain
taxa to measured metabolite levels [40], we determined
here exactly which strains were producing the bile acids
in the individual microbiome models using the afore-
mentioned simulation results. Overall, 198 strains con-
tributed to total production flux of at least one bile acid
in at least one microbiome model (Additional file 1:
Table S8). Of those, 15 strains contributed in > 90% of
communities across both cohorts and thus play a signifi-
cant role in bile acid metabolism. These strains included
known commensals, such as Ruminococcus gnavus
ATCC 29149, Coprococcus comes ATCC 27758, Faecali-
bacterium prausnitzii L2_6, Clostridium sp. M62_1, Eu-
bacterium ventriosum ATCC 27560, Bacteroides
pectinophilus ATCC 43243, and Dorea formicigenerans
ATCC 27755. A variety of Bacteroides strains performed
bile acid deconjugation and 7-keto-DCA/7-dehy-
dro-CDCA biosynthesis, and their contribution was sig-
nificantly depleted in the IBD microbiomes (p values for
all < 0.01, Additional file 1: Table S7). Consistently, a
positive correlation between Bacteroides spp. and sec-
ondary bile acid biosynthesis was found [36]. Using a
Principal Coordinates Analysis on the strain-level contri-
butions, we observed a clear separation between the IBD
patients and controls (Fig. 3d), as well as between the
HMP individuals and the pediatric individuals, due to the
difference in strains (Fig. 3d, Additional file 2: Figure S7).
The strain difference is most likely due to differences in
age, location, and ethnicity of the two cohorts. On the
phylum level, the contributions in both the healthy adult
and healthy pediatric microbiomes were mostly driven by
Actinobacteria, Bacteroidetes, and Firmicutes representa-
tives, as expected, while Proteobacteria contributed signifi-
cantly in the IBD microbiomes (p values for all < 0.05,
Additional file 1: Table S7 and Additional file 2: Figure S7).
A Wilcoxon rank sum test adjusted for FDR on strain-level
contributions revealed that 303 strain-level contributions
Table 2 Overview of the 194 personalized microbial community models generated within this study.
Average number ± standard deviation Minimum Maximum
Microbes 127 ± 38 21 316
Reactions 141,727 ± 409,31 24,805 366,932
Metabolites 127,190 ± 371,22 21,967 328,108
Coupling constraints 200,618 ± 586,12 33,224 521,077
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differed significantly between dysbiotic IBD and healthy
pediatric microbiomes (p value < 0.05, Additional file 1:
Table S7). Strain contributions mostly depleted in the IBD
microbiomes included those of Bacteroides vulgatus ATCC
8482, Ruminococcus (Blautia) torques L2-14, Faecalibacter-
ium prausnitzii strains, Eubacterium rectale strains, Rumi-
nococcus sp. SR1-5, and Clostridium sp. M62-1 (p values
for strains were < 0.001, Additional file 1: Table S7). The
IBD microbiomes had significantly lower deconjugated CA
and CDCA contributions by Actinobacteria and Bacteroi-
detes representatives (p values < 0.05, Additional file 1:
Table S7 and Additional file 2: Figure S7). The contribution
of 12-dehydro-CA production flux, which was significantly
reduced in the IBD microbiomes (p value < 0.001,
Additional file 1: Table S7) was attributed mostly to repre-
sentatives of the Lachnospiraceae and Ruminococcaceae
families, which are considered to be beneficial due to con-
taining many butyrate producers [41]. These representa-
tives included two Faecalibacterium prausnitzii strains (p
value < 0.001), a species well known to be depleted in IBD
[42]. In contrast, the overall 7-dehydro-CA production po-
tential was comparable between the IBD and the healthy
pediatric microbiomes (Additional file 1: Table S7). How-
ever, the strains contributing were different, with reduced
contributions by commensal bacteria to the production of
7-keto-DCA/7-dehydro-CDCA, and increased contribu-
tions of the pathogenic Escherichia coli strains O157-H7
Sakai and UTI89 UPEC (Additional file 1: Table S7). These
two strains contributed significantly higher to deconjuga-
tion and 7-keto-DCA/7-dehydro-CDCA production in the
IBD microbiomes (p value < 0.001, Additional file 1: Table
S7). Taken together, the dysbiotic IBD microbiomes, com-
pared to the healthy control microbiomes, were depleted in
contributions of a variety of commensal microbes to bile
salt hydrolase and to bile acid biotransformation but
enriched in contributions of pathogenic Escherichia sp.
(Additional file 1: Table S7). Thus, the IBD microbiomes
had distinct bile acid deconjugation and transformation
potential, consistent with reports that bile acid compos-
ition in IBD patients is abnormal [5]. In total, 488 analyzed
features, which encompasses total production, strain con-
tributions, and reaction abundances, were significantly dif-
ferent (p-value <0.05), of which 375 were highly
significant (p-value <0.001) (Additional file 1: Table S7).
Shadow price analysis identifies individual-specific
bottlenecks in bile acid biotransformation potential.
To test whether the bile acid production potential could
be directly predicted from the abundance of the metage-
nomics data mapped onto the AGORA reconstruction
(i.e., from the encoding gene abundance), we calculated
the Spearman correlation between the individual pro-
duction potential for the two deconjugated primary and
13 secondary bile acids (Table 1) and the total
community abundance for all reactions in the bile acid
pathway in the 194 community models. Consistently, for
13 of the 15 bile acids, the correlation between produc-
tion potential and the abundance of reaction directly
synthesizing the respective bile acid was 0.96 or higher
(Additional file 1: Table S9). The secondary bile acid
Iso-CA is synthesized from 3-dehydro-CA by 3β-HSDH.
Surprisingly, the Spearman correlation between produc-
tion potential for Iso-CA/Iso-CDCA and the abundance
of the 3β-HSDH reaction (VMH ID: ICA3bHSDHe/
ICDCA3bHSDHe) calculated for all 194 microbiome
models was only 0.18 indicating that the reaction abun-
dance of the producing reaction did not correlate with
production (Additional file 1: Table S9). In fact, only a
minority of the 194 microbiome models with a high
abundance of the 3β-HSDH reaction (VMH ID:
ICA3bHSDHe), all of which were IBD microbiomes, also
had a high Iso-CA production flux (Fig. 4a). Thus, fac-
tors other than 3β-HSDH abundance limited the pro-
duction flux. To identify these factors, the metabolic
fluxes needed to be analyzed in the context of the path-
way and the microbial community. Constraint-based
modeling is ideal for such analyses of metabolic depend-
encies since it is mechanistic on the molecule level and
takes species-species metabolic exchanges and boundar-
ies into account [18].
To identify the factors limiting the production poten-
tial for secondary bile acids, the shadow prices associ-
ated with the flux solutions of each microbiome model
were analyzed. Shadow prices are a standard feature of
constraint-based modeling that are routinely calculated
with each feasible flux balance analysis solution. Briefly,
the shadow price is a measurement for the value of a
metabolite towards the optimized objective function,
which indicates whether the flux through the objective
function would increase or decrease when the availabil-
ity of this metabolite would increase by one unit [7]. A
positive or negative shadow price indicates that
increased availability of the metabolite would either in-
crease or decrease the flux through the objective func-
tion (note that this definition varies by solver),
respectively. In contrast, the availability of a metabolite
with a shadow price of zero has no influence on the flux
through the objective function. To identify limiting
factors for secondary bile acid production, we investi-
gated the shadow prices in the flux balance analysis solu-
tions (see the “Materials and methods” section) when
optimizing the production of the secondary bile acids in
the 194 microbiome models (Fig. 4b, Additional file 1:
Table S10). Nonzero shadow prices with an absolute
value higher than 10−6 indicating importance for bile
acid production flux were found for biomass metabolites
of 129 strains carrying bile acid enzymes, for
strain-specific metabolites in the bile acid pathway, and
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for dietary exchange metabolites of the bile acids. Over-
all, 1138 microbial and dietary metabolites were found
to be relevant for bile-acid synthesis in the entire set of
microbiome models (Additional file 1: Table S10). When
comparing the shadow prices in the three groups, the
number of metabolites with nonzero shadow prices was
significantly lower in the IBD microbiomes than either
in the healthy pediatric or healthy adult microbiomes
(Fig. 4c). Hence, the pediatric IBD patients were
depleted in strains with bile acid biosynthesis capabil-
ities. This result highlights that an increase in secondary
bile acid biosynthesis in these individual communities
could only be achieved by introducing additional micro-
bial strains.
Next, we aimed to identify the factors limiting Iso-CA
biosynthesis potential. Of the reconstructed strains, 16
and 11 strains, respectively, carried the 3α- and 3β-
HSDH enzyme (Additional file 1: Table S1). Five strains
(Eggerthella sp. 1_3_56FAA, Eggerthella lenta DSM
2243, Gordonibacter pamelaeae 7-10-1-bT, Mycobacter-
ium avium subsp. avium ATCC 25291, and Ruminococ-
cus gnavus ATCC 29149) possessed both enzymes. Of
the strains possessing either or both enzymes, 18 were
present in at least one of the 194 microbiome models.
The shadow prices corresponding to Iso-CA production
were inspected (Additional file 1: Table S10). Note that
shadow prices for Iso-CDCA were analogous.
Four scenarios could be distinguished based on the
shadow prices. Seven microbiomes belonging to the first
scenario were unable to synthesize Iso-CA (Additional
file 1: Table S6). Consequently, in these microbiomes,
shadow prices were only nonzero for dietary Iso-CA
(Additional file 1: Table S10) indicating that Iso-CA
levels could only be increased by directly providing it. In
the second scenario, which was found in 19 micro-
biomes, shadow prices for the six strains carrying
3β-HSDH but not 3α-HSDH were nonzero for at least
one of the six strains’ biomass metabolites (Additional
file 1: Table S10). In the same 19 microbiomes, shadow
prices for all eight strains carrying 3α-HSDH but not
3β-HSDH were zero. This result showed that 3α-HSDH
abundance was not a bottleneck and Iso-CA production
could be increased by increasing the abundance of
strains carrying 3β-HSDH. In these microbiomes the
3β-HSDH abundance directly correlated with Iso-CA
production flux, as illustrated with the example of Hol-
demania filiformis DSM 12042 in Fig. 4d. In the third
scenario, which contained the majority of microbiomes
(145 cases), the shadow prices for all six strains carrying
3β-HSDH but no 3α-HSDH were zero. Instead, the
shadow prices for at least one of the eight strains carry-
ing 3α-HSDH but not 3β-HSDH were nonzero. Conse-
quently, in these microbiomes, the availability of the
precursor 3-dehydro-CA was flux-limiting and Iso-CA
production could not be increased by increasing the
abundance of strains carrying only 3β-HSDH. These 145
microbiomes had the lower than expected Iso-CA produc-
tion potential (Fig. 4e). As expected, in all 145 micro-
biomes, the shadow price for dietary 3-dehydro-CA, the
precursor of Iso-CA, was also nonzero (Additional file 1:
Table S10). Finally, in the fourth scenario, which consisted
of 22 microbiomes, shadow prices were nonzero only for
the biomass metabolite of Ruminococcus gnavus ATCC
29149 and in some cases Eggerthella lenta DSM 2243
(Fig. 4f ). These two strains possess both 3α-HSDH
and 3β-HSDH and are present in most microbiomes
in this study. Thus, they played a central role for all
microbiomes’ capabilities to synthesize Iso-CA.
In summary, by analyzing the shadow prices associated
with each flux balance analysis solution when optimizing
for secondary bile acid production, strain-specific contri-
butions to their biosynthesis were determined for each
personalized community model. Four scenarios with dif-
ferent bottlenecks for the biosynthesis of Iso-CA were
identified. This analysis highlights once more that the
metabolic potential of an individual microbiome, and
(See figure on previous page.)
Fig. 4 Metabolic bottlenecks and shadow price profiles computed when optimizing for Iso-CA production in 194 microbiome community
models. a Abundance of the 3β-HSDH reaction yielding Iso-CA (VMH ID: ICA3bHSDHe) plotted against Iso-CA production potential (flux values
are given in mmol gDW−1 h−1) for the 194 microbiomes. b Heat map of the shadow prices retrieved from the 194 microbiomes when the
production of two deconjugated primary and 13 secondary bile acids was optimized. Blue and white data points show nonzero and zero shadow
prices, respectively. The columns show the 194 microbiomes annotated by group. The rows show all metabolites that had a nonzero shadow
price in at least one community model. The metabolites are annotated by taxonomy. Entries annotated with “Diet_metabolite” represent bile acid
metabolites present in the dietary, luminal, or fecal compartment of the microbiome model. The “bile acid optimized” color bar shows the bile
acid for which production was optimized. c Number of metabolites with nonzero shadow prices in the microbiome models of healthy adults, IBD
patients, and healthy pediatric controls. Significant difference (p value < 0.001) is indicated by stars. d Shadow prices for the biomass metabolite
of Holdemania filiformis DSM 12042, a strain carrying 3α-HSDH but not 3β-HSDH, plotted against Iso-CA production and abundance of the 3β-
HSDH reaction. Blue dots indicate models belonging to Scenario 2 (see main text). e Shadow prices for the biomass metabolite of Collinsella
aerofaciens ATCC 25986, a strain carrying 3β-HSDH but not 3α-HSDH, plotted against Iso-CA production and abundance of the 3β-HSDH reaction.
Blue dots indicate models belonging to Scenario 3 (see main text). f Shadow prices for the biomass metabolite of Ruminococcus gnavus ATCC
29149, a strain carrying both 3α-HSDH and 3β-HSDH, plotted against Iso-CA production and abundance of the 3β-HSDH reaction. g Pathway for Iso-
CA biosynthesis from Glyco-or Tauro-CA, and depiction of the steps representing bottlenecks in Scenarios 2 and 3 (see main text). For metabolite
abbreviations see Table 1. For simplicity, sections of the y axis without any data are omitted in a and d–f (indicated by the two gray lines).
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strategies to manipulate this metabolic potential, cannot
be inferred solely from the abundance of single genes
and depends on the community-wide metabolic network
as well as metabolic constraints (e.g., substrate availability).
We demonstrated that constraint-based modeling allows
for the generation of mechanistic, testable hypotheses.
Discussion
In this work, we used a systematic computational mod-
eling workflow to investigate the bile acid production
capabilities of gut microbes and gut microbial communi-
ties. After annotating and reconstructing the bile acid
deconjugation and transformation pathways (Fig. 1a, Fig.
2) in 693 human gut microbe genomes, we first built
pairwise microbial models providing novel insight into
strain-specific bile-acid production capabilities. We then
assembled gut microbiome models for each metage-
nomics sample of either healthy individuals or pediatric
IDB patients. The three key results of our analysis are as
follows: (1) microbes can complement each other’s bile
acid pathway to achieve the broader bile acid production
repertoire observed in fecal samples, (2) bile acid produc-
tion profiles of 194 microbiome models were
individual-specific and distinguished healthy controls from
pediatric IBD patients, and (3) the bile acid production
profiles could not be predicted by reaction (gene) abun-
dance alone, as illustrated for Iso-CA illustrating the
added value of computational modeling of metabolite
production capabilities of microbial communities.
While it can be intuitively understood that bile acid
biosynthesis is a cooperative task in the gut microbiome
from the known fact that no strain possesses the
complete pathway [23], these microbe-microbe meta-
bolic dependencies could be exactly predicted through
constraint-based modeling yielding more than 7000 pairs
of microbes (Fig. 3a, Additional file 1: Table S5). The
capabilities of most strains to generate secondary bile
acids were shown to be very limited. For example, no
strain alone but 100 pairs could convert tauro-or
glyco-CDCA into UDCA (Additional file 1: Table S5).
This analysis demonstrated that strain-specific
microbe-microbe interactions need to be considered
when studying the metabolic crosstalk between the gut
microbiome and the mammalian host. Similar microbial
corporations through cross-feeding of metabolic prod-
ucts have been suggested, e.g., for intestinal microbial
metabolism of b-vitamins [43], of host-derived mucins
[44], of dietary glycans [45], of flavonoids [46], for
short-chain fatty acid production [41], and for microbial
respiratory capabilities [47].
The personalized bile acid metabolism profile of 194
microbiomes, which included the total production
potential and the strain-level contributions to overall
production was individual-specific and distinct from
healthy controls in pediatric IBD patients (Fig. 3b–d,
Additional file 2: Figure S7). Our finding that the bile
acid profiles of IBD patients differ from healthy controls
agrees with experimental reports. For instance, a recent
study has investigated the microbiomes and fecal meta-
bolomes of pediatric IBD patients and their relatives and
could distinguish two metabotypes both in patients and
relatives [48]. The IBD-associated metabotype has been
characterized by an altered bile acid profile, with
increased levels of cholate and sulfated and taurine-con-
jugated primary bile acids. The altered bile acid profile
suggests a reduced bile acid deconjugation and conver-
sion potential of the gut microbiota [48], which we could
demonstrate being the case with our in silico results
(Fig. 3b–c).
In most analyzed microbiome models, the production
potential for Iso-CA was found to be lower than ex-
pected from the abundance of the 3β-HSDH. Analyzing
the shadow prices [7] revealed that the presence of
strains capable of synthesizing the precursor 3-dehydro-
CA was a bottleneck in many microbiomes. In fact, we
identified four scenarios, for which different strategies
could be used to increase overall Iso-CA production
capabilities in a given microbiome. In these four scenar-
ios, Iso-CA production flux could be increased (1) only
by directly providing it, (2) by increasing the abundance
of strains carrying 3β-HSDH, (3) either by providing
3-dehydro-CA or by increasing the abundance of strains
carrying 3α-HSDH, and (4) by increasing the abundance
of Ruminococcus gnavus ATCC 29149 and in some cases
Eggerthella lenta DSM 2243. To complete the systems
biology cycle, these predictions require experimental
validation, e.g., by measuring the amount of Iso-CA
levels in in vitro cultures from fecal samples. A shadow
price analysis has the advantage of being an unbiased
indicator for metabolites in a pathway that are of key
importance for the end product of the pathway. It
could be readily applied to other health-relevant me-
tabolites produced by the gut microbiome (e.g.,
short-chain fatty acids) and key synthesis-limiting steps
in the relevant pathways.
Compared with commonly used computational and
multivariate statistical approaches, the constraint-based
modeling approach applied in this study has several key
advantages. First of all, unlike quantifications of total
gene abundance (e.g., [49]) and correlation-based ap-
proaches (e.g., [50]), our approach is mechanistic and
obeys physicochemical and environmental constraints
(e.g., mass-charge conservation, laws of thermodynam-
ics, substrate uptake). This property enabled us to pre-
dict the metabolic capabilities of a given microbial
community, as defined by metagenomics data. Import-
antly, the predicted capabilities are physiologically, phys-
icochemically, and thermodynamically feasible under the
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given medium conditions (i.e., diet). Second, the meta-
bolic reconstructions used in our approach are
strain-resolved, and the capabilities included in each
metabolic network are based on the microbes’ genome,
detailed comparative genomic analyses as well as an ex-
tensive review of the literature for biochemical and
physiological data [15]. As a consequence, the metabolic
contribution of each strain in each individual micro-
biome can be exactly predicted with high confidence.
Another advantage of our approach is the incorporation
of species-species boundaries and transport capabilities.
As stated above, species-species cross-feeding plays a
key role for the metabolic potential of a microbial com-
munity and thus needs to be considered. Finally, it is
challenging to link typical metagenomics-based ap-
proaches to a particular host function. Microbial species
or functions can be correlated with certain host metabo-
lites through top-down multivariate statistical analyses
[50]. However, mechanisms explaining these correlations
are often lacking. As more omics data become available
for microbiome samples, the generated microbiome
models can be further constrained and personalized
through the integration of meta-transcriptomic [51],
meta-metabolomic [52], meta-proteomic data [53], or
nutritional information via the Virtual Metabolic Human
database [16]. The microbiome models can also be inte-
grated with the global human reconstruction, Recon3D,
which includes a secondary bile detoxification subsystem
[54], or with the whole-body organ-resolved reconstruc-
tion of human metabolism [19] thanks to the use of a
consistent namespace [15]. The integrated analysis can
predict organ-specific metabolic changes due to differences
in microbial community composition and yield novel hy-
potheses about host-microbiome co-metabolism [19].
One limitation of the method is the steady-state
assumption of flux balance analysis and the resulting
computation of fluxes rather than concentrations. More-
over, the AGORA reconstructions and our modeling
framework do not include regulatory constraints and
kinetic parameters. As a result, the modeling framework
does not account for substrate specificity and trans-
porter capacity, although the latter could be incorpo-
rated as reaction constraints dependent on data
availability. This limitation could be overcome using hy-
brid modeling techniques that integrate the dynamics
and the regulation of biochemical processes through
with differential equations [55–58]. Furthermore, our
method does not allow predicting microbial composition
or organismal abundances in the microbiome, again due
to the steady-state assumption. The method relies on
parameterizing the personalized models with the relative
microbial abundances calculated from the metagenomic
data. For predicting microbial abundances, dynamic
community flux balance analysis methods [58, 59] are
more appropriate. Consequently, we focus the applica-
tion of our framework on exploring the metabolic profile
of a given gut microbiome with known microbial
composition. Finally, it is well known that the gut micro-
biome fluctuates over time [60], however, each simula-
tion performed with the personalized models only
represents the fecal microbiome at a single time point.
This is expected as the fecal metagenomic sample that
serves as the input data also only captures the gut
microbiome at a single time point. Fecal metagenomic
samples from the same individuals at multiple time
points are, for example, available in [61]. Such data
could be used to model a time series of metabolic states
and elucidate how the gut microbial metabolic profiles
fluctuate over time.
Flux profiles predicted by the framework can be read-
ily compared with qualitative increases or decreases in
metabolites in disease conditions to validate simulation
results, which would require metagenomic or 16S rRNA
data as well as fecal metabolomics from the same sub-
jects. Metagenomic and fecal metabolomic measure-
ments of bile acids have been performed in [62] and
such data could be linked through modeling in future ef-
forts. Such comparisons have valuable applications for
mechanistically linking metagenomic and metabolomic
measurements from the same sample. Moreover, qualita-
tive and quantitative metabolomic data could be used as
input data to contextualize the models further. A
COBRA Toolbox module for the implementation of
metabolomic data with constraint-based models has
been developed [52].
While the scope of the present work is the prediction
of bile acid metabolism, in future efforts, other
health-relevant microbial metabolic subsystems may be
considered. For instance, Lewis et al. found that several
pathways, e.g., glycerophospholipid metabolism, amino
benzoate degradation, sulfur relay system, and glutathi-
one metabolism, separated healthy and dysbiotic micro-
biomes [36]. In a follow-up work, fecal amino acid levels
have been found to be altered in IBD patients and to
positively correlate with Proteobacteria [40]. Applying
the computational workflow presented in this study to
predict the gut microbial metabolome beyond bile acid
metabolism would allow us to mechanistically link al-
tered metabolites with strain-specific capabilities. Ultim-
ately, such analysis could lead to novel insights into the
mechanisms behind altered metabolomes in disease
states and allow pinpointing disease-relevant species
and/or enzymes that may serve as novel drug targets.
Conclusions
We demonstrated that an in silico metabolic modeling
workflow could elucidate the metabolic potential of an
individual’s microbiome, which cannot be done based on
Heinken et al. Microbiome            (2019) 7:75 Page 13 of 18
gene count and reaction abundance alone. We illustrated
this workflow using metagenomics data of healthy indi-
viduals and IBD patients while focusing on bile acid
metabolism. Importantly, we were able to demonstrate
that this mechanistic, strain- and metabolite-resolved,
unbiased, and inexpensive approach allows for the sys-
tematic interrogation of the metabolic potential of an in-
dividual’s microbiome and can yield testable novel
hypotheses. Integrative systems biology approaches are
urgently needed to gain novel insight into complex,
multifactorial diseases, such as IBD [1]. In future efforts,
personalized modeling could also be applied to predict-
ing individual-specific dietary or therapeutic interven-
tions [63]. The AGORA resource, the COBRA Toolbox,
and the Microbiome Modeling Toolbox are freely avail-
able to the scientific community. We have also created
extensive tutorials (available at the COBRA Toolbox
GitHub) aiding users interested in applying our frame-
work. We expect that the metabolic modeling approach
presented will have valuable applications in unraveling
the role of human-gut microbiome metabolic interac-
tions in human health and disease.
Materials and methods
Comparative genomic approach
All 773 strains of the AGORA resource [15], 46 strains
reconstructed in this study, and 23 currently not recon-
structed strains were analyzed for the presence of their
genomes at the PubSEED resource [26, 27], resulting in
690 bacterial and three archaeal genomes to be consid-
ered in this study (Fig. 1a). Note that only 670 of the re-
constructed microbes had their genomes available in
PubSEED and were consequently used for the compara-
tive genomic approach. All 693 human gut microbe
genomes were analyzed for the presence of orthologs of
bile acid deconjugation and biotransformation genes
(Additional file 1: Table S1). Orthologs are defined as
genes that satisfy the following conditions: (1) Orthologs
should be closely homologous proteins (e-value cutoff =
e−50). (2) Orthologs should be found in the same gen-
omic context, i.e., the structure of gene locus should be
conserved in related genomes. (3) Orthologs should
form a monophyletic branch of a phylogenetic tree.
For the search of homologs and analysis of genomic
context, the PubSEED platform was used along with
phylogenetic trees for protein domains in MicrobesOn-
line [64]. Multiple protein alignments were performed
using the MUSCLE v. 3.8.31 tool [65, 66]. Phylogenetic
trees were constructed using the maximum-likelihood
method with the default parameters implemented in
PhyML-3.0 [67]. The obtained trees were visualized and
midpoint-rooted using the interactive viewer Dendro-
scope, version 3.2.10, build 19 [68].
The following previously analyzed genes were used as
a starting point: (1) genes for bile salt BSH from mul-
tiple genomes [21], (2) 7α–HSDH) from Bacteroides
fragilis [22], (3) 3α- and 3β-HSDHs genes from
Eggerthella lenta DSM 2243 and Ruminococcus gnavus
ATCC 29149 [23], (4) 7α-HSDH and baiABCDEFGHI
genes for a multistep 7α/β-dehydroxylation pathway, (5)
bai genes from Eggerthella lenta DSM [23], (6)
7β-HSDH gene from Clostridium absonum [25], and (7)
12α-HSDH from Clostridium hylemonae DSM 15053,
Clostridium scindens ATCC 35704, and Clostridium hir-
anonis DSM 13275 [24]. Note that Clostridium leptum
has been experimentally shown to have 12α-HSDH
activity [28]; however, we were unable to identify the
12α-HSDH gene in its genome. BSH proteins are closely
related to the penicillin V amidase (PVA) proteins [21].
To avoid mis-annotations, a phylogenetic tree for BSH
proteins and their homologs in the analyzed genomes
was constructed (Additional file 2: Figure S1), and ortho-
logs of the known BSH genes were identified. All HSDH
proteins listed above demonstrated similarity to each
other and with BaiA proteins. Thus, orthologs for
HSDH/BaiA proteins were resolved through the
construction of a phylogenetic tree (Additional file 2:
Figure S2). Finally, two new genes in the 7α/β-dehydrox-
ylation pathway (BaiO and BaiP, Fig. 2) were predicted
in this work. All of the annotated genes are represented
as a subsystem at the PubSEED website [69] and can be
found in Additional file 1: Table S1.
Formulation and addition of reactions
Reaction mechanisms were retrieved from the KEGG
database [70] as well as published literature (e.g., [71]).
For all genomes having genes for BSH, HSDHs, or the
complete 7α/β-dehydroxylation pathway (Fig. 2), meta-
bolic mass- and charge-balanced reactions were formu-
lated. Exchange reactions were added for all extracellular
metabolites. Most reactions were associated with genes
and proteins annotated in the analyzed genomes. Reac-
tions not-associated with genes and proteins were only
added if the gene was unknown but the reaction was
required to eliminate dead-ends in a metabolic pathway.
Thus, the following gap-filling reactions were added
without associations with genes or proteins: (1) A trans-
port reaction for LCA, the final product of 7α/β-dehy-
droxylation pathway which was added as the transporter
is unknown. (2) Pathways that yield allolithocholate
(allo-LCA) and allodeoxycholate (allo-DCA) were in-
cluded for strains possessing the bai gene cluster as these
compounds are known to be side-products of the 7α/
β-dehydroxylation pathway [72] and found in human
adults under certain circumstances [3].
Pathways for cholesterol reduction to coprostanol
were also reconstructed. These enzymatic activities, both
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cytoplasmic and extracellular, have been shown in Lacto-
bacillus acidophilus, Lactobacillus bulgaricus, and Lacto-
bacillus casei [73]. The precise mechanisms of these
reactions as well as the enzyme-encoding genes are
unknown, but the biotransformation has been shown to
be associated with the oxidation of NADH to NAD+
[73]. Consequently, reactions for extracellular and cyto-
plasmic NADH-dependent reduction of cholesterol to
coprostanol were added to six Lactobacillus sp. models,
together with exchange reactions for cholesterol and
coprostanol as well as a predicted transport reaction for
cholesterol uptake.
All metabolites and reactions were formulated following
an established reconstruction protocol [8]. Metabolites
and reaction abbreviations in the bile acid subsystem were
created in accordance with the Virtual Metabolic Human
(VMH) [16] nomenclature to ensure compatibility with
the human metabolic reconstruction. The MATLAB-
based reconstruction tool rBioNet [74], which ensures
quality control and quality assurance, such as mass- and
charge-balance, was used to add the metabolites and reac-
tions to the appropriate reconstructions. All reactions and
metabolites in the reconstructed bile acid subsystem are
described in Additional file 1: Table S2a, b.
Expansion of AGORA
A total of 46 gut microbial strains were newly recon-
structed. The reconstructions were generated by
semi-automatically expanding and curating KBase [75]
draft reconstructions following the established AGORA
pipeline used in [15] (Additional file 1: Table S11). Of
the 773 AGORA strains and 46 newly reconstructed
strains, 232 strains total carried at least one gene in the
bile acid pathway (Additional file 1: Table S1) and six
produced coprostanol. The corresponding reconstruc-
tions were expanded by the appropriate metabolites and
reactions using rBioNet [74] and subjected to extensive
quality-assurance and control measures [8, 32] (Fig. 1a).
The expanded resource, accounting for 818 strains, is
available on the Virtual Metabolic Human website [16].
Construction of pairwise models
The 232 AGORA reconstructions carrying bile acid reac-
tions were joined pairwise in every possible combination
as described previously [15] using the Microbiome
Modeling Toolbox [33]. In total, 26,796 pairwise models
were created.
Construction of sample-specific gut microbiota models
Metagenomic datasets from 194 samples in total were
obtained from three sources: (1) Strain-specific relative
abundance data from 149 individual microbiotas of
healthy American individuals was obtained from the
Human Microbiome Project website [35]. (2) Paired-end
Illumina raw reads of 33 dysbiotic Crohn’s Disease
patients in the PLEASE cohort [36] and of 26 healthy
controls in the COMBO cohort [37] were retrieved from
NCBI SRA under SRA: SRP057027. For the latter data-
set, the reads had been pre-processed and then mapped
onto the reference set of 773 AGORA genomes, as
described in [38]. To reduce the number of false posi-
tives, a cutoff of 10% genome coverage was applied to
the resulting coverages (representing a threshold of at
least 10% genome coverage for each microbe in each
human individual). The resulting coverages were
normalized for each individual in order to obtain the
relative abundances. To avoid too small model sizes,
microbiome models, for which less than 20 strains could
be mapped to the reference set of AGORA genomes,
were excluded from the analysis. This was the case for
13 samples from the PLEASE cohort and one sample
from the COMBO cohort.
Personalized microbiome models were then created
using the mgPipe module in the Microbiome Modeling
Toolbox [33] (Fig. 1b). Briefly, for all strains identified in
at least one metagenomics sample, the corresponding
AGORA reconstructions, if available, were joined into
one global constraint-based microbiome community re-
construction as described elsewhere [17, 33]. For each of
the 194 metagenomic samples, the list of all the mapped
strains and their strain-level abundances served as input
data for deriving a personalized microbiota model from
the global community reconstruction, which consisted of
the joined AGORA reconstructions corresponding to
each strain present in the sample. The flux through each
AGORA strain’s model was coupled to its respective bio-
mass objective function, as described elsewhere [11].
Then, we parameterized the community biomass reac-
tion by applying the strain-level abundances as stoichio-
metric values for each microbe biomass reaction in the
community biomass reaction (Fig. 1b). These constraints
enforced that all strains grew at the experimentally mea-
sured ratios. Subsequently, an Average European diet
supplemented with conjugated primary bile acids (see
below) was applied as constraints on the dietary ex-
changes. To simulate a realistic turnover of microbial
biomass, the allowed flux through the community
biomass reaction was set to be between 0.4 and 1 mmol
× person-1 × day-1, corresponding to a fecal emptying of
once every three days to once a day. The features of the
personalized community models are given in Table 2.
Definition of the average European diet
A diet representing the nutrient intake of an average
European individual was obtained from the nutrition re-
source in the Virtual Metabolic Human database [16]
along with the corresponding flux values. The diet was
supplemented with metabolites previously determined
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necessary for the biomass production of at least one
AGORA reconstruction [15]. Each microbiota commu-
nity model was constrained with the Average European
diet using a dedicated function in the Microbiome
Modeling Toolbox [33] (adaptVMHDietToAGORA.m).
Additionally, to enable modeling of bile acid transform-
ation, the uptake of the conjugated primary bile acids
Glyco-CA (VMH ID: gchola), Tauro-CA (VMH ID:
tchola), Glyco-CDCA (VMH ID: dgchol), and
Tauro-CDCA (VMH ID: tdchola) was allowed to be
taken up unlimitedly by setting the lower bounds on
the corresponding exchange reactions to − 1000 mmol
× person-1 × day-1. The lower bounds on all other
dietary exchange reactions were set to zero preventing
the uptake of these metabolites. The constraints im-
plemented to simulate the diet are given in Additional
file 1: Table S3.
Interrogation of models for bile acid synthesis capabilities
The bile acid production potential in 232 AGORA re-
constructions and 26,796 pairwise models was deter-
mined using FBA [9]. To predict the maximally possible
bile acid production flux, the exchange reactions (in the
single and pairwise models) and the fecal secretion reac-
tions (in the community models) for CA, CDCA, and 13
secondary bile acids were individually chosen as the ob-
jective function and maximized. The 194 sample-specific
community models were interrogated using distribu-
tedFBA [76]. To determine the total maximal production
potential, the maximal flux through the fecal exchange
reactions in the community models was maximized. To
retrieve the contribution of each individual strain to
overall production, the minimal fluxes through the
luminal exchange reactions of each joined AGORA
model (representing secretion into lumen) were ex-
tracted. Shadow prices were retrieved from each com-
puted flux balance solution [7]. To extract the shadow
prices for all metabolites in the respective community
model that were computed while maximizing the pro-
duction flux of secondary bile acids, a dedicated function
(analyseObjectiveShadowPrices.m) in the Microbiome
Modeling Toolbox [33] was used.
Simulations
Model creation and contextualization, and simulations
were carried out using the COBRA Toolbox [34] and the
Microbiome Modeling Toolbox [33] in MATLAB
version 2016b (Mathworks, Inc.) as programming envir-
onment. Flux balance analysis (FBA) [9] for pairwise
simulations was performed using the optimization solver
CPLEX through the Tomlab (Tomlab, Inc.) interface for
MATLAB. Distributed flux balance analysis (distribu-
tedFBA) [76] for personalized microbiome simulations
was performed using the IBM CPLEX solver (IBM, Inc.)
through the CPLEX interface for Julia.
Data analysis
The calculation of the Spearman correlation and the
two-sided Wilcoxon rank-sum test was performed in
MATLAB version 2016b (Mathworks, Inc.) using the
corr and ranksum functions, respectively. The p values
were adjusted for false-positive discovery rate with the
Benjamini-Hochberg method using the mafdr function
in MATLAB. Heatmaps were generated with R version
3.3.2 [77] using the aheatmap, pheatmap, ggplot2, easy-
Ggplot2, and RColorBrewer packages, as well as the
ComplexHeatmap package in Bioconductor 2.7 (http://
www.bioconductor.org/). Principal Coordinates Analysis
(PCoA) was performed with the vegan package in R
using the Bray-Curtis dissimilarity index. Other plots
were generated with MATLAB.
Additional files
Additional file 1: Table S1. Bile acid deconjugation and transformation
genes identified in the 693 analyzed genomes. Table S2. Description of
the bile acid metabolism subsystem reconstructed for AGORA: a)
metabolites, b) reactions. Table S3. Constraints implemented to simulate
the Average European (AE) diet supplemented with taurocholate,
glycocholate, taurochenodeoxycholate, and glycochenodeoxycholate.
Table S4. Bile acid production potential for each of the 232 AGORA
models carrying bile acid reactions. Table S5. Secondary bile acids
produced in pairwise AGORA models that could not be produced
individually by either model. Table S6. Bile acid production potential
(mmol × person-1 × day-1) predicted for the community models
representing 194 human microbiomes. Table S7. Features that
significantly differed between 15 pediatric Crohn's Disease patients and
25 healthy controls. Table S9. Correlations between total community bile
acid production (mmol × person-1 × day-1) and total community reaction
abundance across all 194 community models. Table S10. Shadow prices
in the flux balance solutions when optimizing for secondary bile acid
production in all community models. Shown are metabolites that had a
nonzero shadow price in at least one model. Table S11. Description of
newly reconstructed strains in this study as an update to the AGORA
resource. (XLSX 2194 kb)
Additional file 2: Figure S1. Maximum-likelihood phylogenetic tree for
bile salt hydrolase (BSH) proteins and their homologs in 693 analyzed hu-
man gut microbe genomes. Figure S2. Maximum-likelihood phylogen-
etic tree for hydroxysteroid dehydrogenase (HSDH)/ bai cluster proteins
and their homologs in 693 analyzed human gut microbe genomes. Fig-
ure S3. Genomic organization of baiNOP containing loci. Figure S4.
Maximal-likelihood phylogenetic tree for homologs of the BaiN protein in
693 analyzed human gut microbe genomes. Figure S5. Maximal-
likelihood phylogenetic tree for homologs of the BaiO protein in 693 ana-
lyzed human gut microbe genomes. Figure S6. Maximal-likelihood
phylogenetic tree for homologs of the BaiP protein in 693 analyzed hu-
man gut microbe genomes. Figure S7. Heat map of the strain-level con-
tributions clustered in Fig. 3d, and presented in Additional file 1: Table S8.
(DOCX 3573 kb)
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